# START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

> **NCT05492682** · PHASE1 · RECRUITING · sponsor: **Valo Therapeutics Oy** · enrollment: 15 (estimated)

## Conditions studied

- Melanoma (Skin)
- Triple-Negative Breast Cancer
- Non-Small Cell Lung Cancer
- Synovial Sarcoma
- Myxoid Liposarcoma
- Colorectal Cancer
- Osteosarcoma
- Sarcoma

## Interventions

- **DRUG:** PeptiCRAd-1
- **DRUG:** Cyclophosphamide
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT05492682
- **Lead sponsor:** Valo Therapeutics Oy
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-02
- **Primary completion:** 2027-04-30
- **Final completion:** 2027-05-31
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05492682

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05492682, "START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer". Retrieved via MORVS 2026-10-17 from https://api.morvs.ai/clinical/NCT05492682. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*